

Supplementary Table 18: Goodness of fit statistics for IPW comparison of 2L UC patients

Characteristic	Difference (ADA – IFX) ¹	95% CI ¹	Difference (GOL – IFX) ¹	95% CI ¹	Difference (TOF – IFX) ¹	95% CI ¹	Difference (UST – IFX) ¹	95% CI ¹	Difference (VDZ – IFX) ¹	95% CI ¹
Patient Sex	0.00	–0.31, 0.31	0.01	–0.31, 0.33	0.09	–0.22, 0.40	0.02	–0.29, 0.33	0.00	–0.31, 0.31
Patient Age	0.02	–0.29, 0.33	Not avail- able	Not avail- able	0.10	–0.21, 0.40	0.02	–0.29, 0.33	0.02	–0.29, 0.33
CCI	–0.11	–0.42, 0.20	–0.10	–0.42, 0.22	–0.06	–0.37, 0.25	–0.03	–0.34, 0.28	0.01	–0.30, 0.32
Number of cortico- steroid prescriptions	–0.01	–0.32, 0.30	–0.11	–0.42, 0.21	–0.09	–0.40, 0.22	–0.03	–0.34, 0.28	0.02	–0.29, 0.33
Number of hospital- izations	0.05	–0.26, 0.36	0.03	–0.29, 0.35	–0.08	–0.38, 0.23	–0.04	–0.35, 0.27	0.01	–0.30, 0.32
Number of comor- bidities	–0.03	–0.34, 0.28	0.04	–0.28, 0.36	0.02	–0.29, 0.33	0.02	–0.29, 0.33	–0.02	–0.33, 0.29
Number of injuries in follow-up	–0.06	–0.37, 0.25	–0.05	–0.37, 0.27	–0.30	–0.61, 0.01	–0.24	–0.56, 0.07	–0.04	–0.35, 0.27

ADA= Adalimumab CCI = Charlson Comorbidity Index CI = Confidence Interval IFX = Infliximab IPW = inverse probability weighting GOL= Golimumab TOF= Tofacitinib UC = Ulcerative Colitis UST= Ustekinumab VDZ= Vedolizumab

¹Standardized Mean Difference